Exclusion of patients based on the lack of ACEi/ARBs use
CKD
When selecting patients for the present analysis, we arrived at a number of 65,168 patients with CKD in the DPV/DIVE cohort. Of these, only 28,359 patients were prescribed either ACEi or ARBs, leaving 56.5% without any blockade of RAS despite CKD although guidelines recommend their use [